<em>In vitro</em> and <em>in vivo</em> pharmacodynamic activity of the new compound XC221GI in models of the viral inflammation of the respiratory tract

The viruses that most commonly affect human respiratory tract include rhinoviruses, syncytial (RSVs), influenza, and coronaviruses (CoVs). virus infection of the epithelial cells triggers an inflammation accompanied by release pro-inflammatory cytokines/chemokines including IL6, IL8 (CXCL8), IL1?, tumor necrosis factor ? (TNF?). transition to acute inflammatory phase in lungs is increase production cytokines, influx neutrophils T into lungs, induction chemokines – CXCR3 receptor ligands main participants generalized inflammation. We studied pharmacodynamic activity new compound XC221GI its effect on IL6 course experimental RSV vitro lung carcinoma A549 vivo cotton rats. also CXCL10, CXCL9, CXCL11 mouse bronchoalveolar lavage as well after intranasal administration interferon ? (IFN?). obtained results demonstrate anti-inflammatory XC221GI, which suppresses excessive key markers IL8, thereby reducing pathology. These data confirm effectiveness a medicine for preventive therapy during viral tract.